1
Clinical Trials associated with PfAMA-1-FVO[25-545]Randomized Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Pichia Pastoris-Expressed P. Falciparum Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) Versus Tetanus Toxoid, in Healthy Malian Adult in Bandiagara
This study will be the first time that the candidate malaria vaccine Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) will be tested in malaria endemic populations. The phase Ib study will include adults who will be randomly allocated to either receive the malaria vaccine or the vaccine against Tetanus. Each participant will receive 3 immunizations, without the clinical investigators or the participants themselves knowing what has been given. They will then be follow-up up for immediate reactions to vaccination, and also over a longer term of one year. Blood will be taken to evaluate the biological safety parameters and also immune responses.
100 Clinical Results associated with PfAMA-1-FVO[25-545]
100 Translational Medicine associated with PfAMA-1-FVO[25-545]
100 Patents (Medical) associated with PfAMA-1-FVO[25-545]
100 Deals associated with PfAMA-1-FVO[25-545]